Titan Biotech Limited
Titan Biotech Limited Fundamental Analysis
Titan Biotech Limited (TITANBIO.BO) shows weak financial fundamentals with a PE ratio of 76.55, profit margin of 14.13%, and ROE of 17.60%. The company generates $1.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze TITANBIO.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentTITANBIO.BO demonstrates superior asset utilization.
Valuation Score
WeakTITANBIO.BO trades at a premium to fair value.
Growth Score
ModerateTITANBIO.BO shows steady but slowing expansion.
Financial Health Score
ExcellentTITANBIO.BO maintains a strong and stable balance sheet.
Profitability Score
WeakTITANBIO.BO struggles to sustain strong margins.
Key Financial Metrics
Is TITANBIO.BO Expensive or Cheap?
P/E Ratio
TITANBIO.BO trades at 76.55 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TITANBIO.BO's PEG of 4.27 indicates potential overvaluation.
Price to Book
The market values Titan Biotech Limited at 12.51 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 56.31 times EBITDA. This signals the market has high growth expectations.
How Well Does TITANBIO.BO Make Money?
Net Profit Margin
For every $100 in sales, Titan Biotech Limited keeps $14.13 as profit after all expenses.
Operating Margin
Core operations generate 15.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.60 in profit for every $100 of shareholder equity.
ROA
Titan Biotech Limited generates $13.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Titan Biotech Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Titan Biotech Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
TITANBIO.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
76.55
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
12.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.82
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.78
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How TITANBIO.BO Stacks Against Its Sector Peers
| Metric | TITANBIO.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 76.55 | 28.45 | Worse (Expensive) |
| ROE | 17.60% | 763.00% | Weak |
| Net Margin | 14.13% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.05 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.78 | 2795.60 | Strong Liquidity |
| ROA | 13.43% | -16588.00% (disorted) | Strong |
TITANBIO.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Titan Biotech Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation